TMD as a Prospective Biomarker for Patients With CRC
By Kai-Keen Shiu, MD, PhD - Last Updated: March 19, 2025Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
Advertisement
Dr. Shiu also highlights his preliminary insights from the translational biomarker studies.
Find the previous comments on Neoadjuvant Pembrolizumab Showing Potential Benefits in Early-Stage dMMR/MSI-High CRC.
Advertisement
Related Posts
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.